Editorial
Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics
Abstract
EGFR mutations are well established as important oncogenic drivers that occur in 10–44% of primary lung adenocarcinomas occurring more frequently in women, Asians and non-smokers (1,2).
